Preclinical studies have shown that ASP‐1929 photoimmunotherapy reshapes the tumor microenvironment to favor antitumor immunity, increasing infiltration of effector CD8+ T cells, reducing suppressive cell populations, and synergizing with anti‐PD‐1 therapy to achieve durable tumor control [15, 16]. Here, CD8A is linked to neoplasm.